On February 28, 2026, the United States and Israel launched major strikes on Iran’s leadership and military infrastructure in a decapitation-style campaign. Read more here.
Regeneron Pharmaceuticals, Inc. is rated a long-term Buy, but I expect near-term sideways trading due to limited new catalysts. Declining Eylea/Eylea HD revenues are largely offset by strong Dupixent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results